ScreenerHero

CABACabaletta Bio, Inc.

NAS · US · Healthcare · Biotechnology · cabalettabio.com
3.130USD+0.97%Mkt Cap: 530.68M $P/E: —

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabt…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap530.68M $
Enterprise Value341.46M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-167.86M $
Revenue/Share—
Last Price3.130 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees154
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.16
PEG—
EV/EBITDA-1.85
EV/Revenue—
P/S—
P/B2.54
EPS (TTM)-1.42
EPS (Forward)-1.48
52W Range
1.40061% of range4.230
52W High4.230 USD
52W Low1.400 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-149.80%
ROA-101.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-131.08M $
CapEx (TTM)1.23M $
FCF Margin—
FCF Yield-18.53%
Net Debt-199.39M $
Net Debt/EBITDA1.08
Balance Sheet
Debt/Equity0.24
Current Ratio5.79
Quick Ratio5.64
Book Value/Sh1.256 USD
Cash/Share1.328 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)13.25 USD
Upside (mean)+323.3%
Target Range3.000 USD – 30.00 USD
$3.000+323.3% to mean$30.00
# Analysts8
Ownership
Shares Out.169.55M
Float141.48M
Insiders0.97%
Institutions94.01%
Short Interest
Short Ratio10.1d
Short % Float27.68%
Short % Out.25.01%
Shares Short40.78M
Short (prev mo.)34.06M
Technical
SMA 502.878 (+8.7%)
SMA 2002.867 (+9.2%)
Beta3.25
S&P 52W Chg18.16%
Avg Vol (30d)3.57M
Avg Vol (10d)4.83M
Technical Indicators
RSI (14)63.7
MACD0.0231
MACD Signal-0.0308
MACD Hist.+0.0539
BB Upper3.040 USD
BB Middle2.781 USD
BB Lower2.522 USD
BB Width18.63%
ATR (14)0.1832 USD
Vol Ratio (20d)1.30x